pheochromocytoma endocrine society guidelines

Pheochromocytoma Endocrine Society Guidelines: Navigating Diagnosis and Management

pheochromocytoma endocrine society guidelines serve as a pivotal resource for clinicians and endocrinologists dealing with this rare but critical adrenal tumor. These guidelines are crafted to ensure accurate diagnosis, effective treatment, and long-term management of pheochromocytoma, which can often present diagnostic challenges due to its variable symptoms and potentially life-threatening complications. Understanding the nuances of these recommendations can significantly enhance patient outcomes and reduce the risk of hypertensive crises.

Understanding Pheochromocytoma and Its Clinical Significance

Pheochromocytomas are catecholamine-producing tumors arising from chromaffin cells in the adrenal medulla. Although relatively rare, their secretion of excessive adrenaline and noradrenaline leads to episodes of severe hypertension, palpitations, headaches, and sweating. Because these symptoms can mimic many other conditions, delays in diagnosis are common.

The importance of adhering to endocrine society guidelines lies in their comprehensive approach to recognizing clinical signs, biochemical testing, imaging, and genetic evaluation. Early identification is crucial as untreated pheochromocytoma can result in hypertensive emergencies, cardiac complications, and increased surgical risk.

Key Components of the Pheochromocytoma Endocrine Society Guidelines

The Endocrine Society’s clinical practice guidelines provide a structured pathway for clinicians to approach suspected pheochromocytoma cases systematically.

1. Clinical Presentation and Suspicion

One of the first steps emphasized is maintaining a high index of suspicion in patients presenting with:

- Paroxysmal or sustained hypertension
- Classic triad of symptoms: headaches, sweating, and palpitations
- Resistant or labile hypertension unresponsive to conventional treatment
- Incidental adrenal masses discovered on imaging
- Family history of pheochromocytoma or related genetic syndromes

Recognizing these hints can prompt timely biochemical screening and prevent complications.

2. Biochemical Testing Recommendations

Biochemical confirmation of pheochromocytoma is the cornerstone of diagnosis. The guidelines prioritize plasma free metanephrines or 24-hour urinary fractionated metanephrines as the most sensitive tests. It is advised to:

- Perform testing during symptomatic periods or when blood pressure is uncontrolled
- Ensure proper patient preparation, avoiding interfering medications or substances
- Interpret results in the context of pre-test probability to minimize false positives

Elevated metanephrine levels guide further imaging and management decisions.

3. Imaging Modalities for Localization

Once biochemical diagnosis is established, localization of the tumor is essential. The Endocrine Society endorses:

- Cross-sectional imaging with computed tomography (CT) or magnetic resonance imaging (MRI) as first-line options
- Functional imaging such as ^123I-metaiodobenzylguanidine (MIBG) scintigraphy or PET scans in specific scenarios, including metastatic disease or extra-adrenal paragangliomas

Proper imaging ensures accurate surgical planning and assessment of tumor extent.

Genetic Testing and Its Role in Pheochromocytoma Management

A significant evolution in the guidelines is the emphasis on genetic evaluation. Up to 40% of pheochromocytomas have an inherited component, associated with syndromes like Multiple Endocrine Neoplasia type 2 (MEN2),

von Hippel-Lindau disease, and neurofibromatosis type 1.

Why Genetic Testing Matters

- Identifies patients at risk for multifocal or bilateral tumors
- Guides surveillance for associated neoplasms
- Facilitates family member screening and counseling

The Endocrine Society recommends offering genetic testing to all patients diagnosed with pheochromocytoma, regardless of age or family history, to tailor personalized care.

Preoperative Preparation and Surgical Management

Surgery remains the definitive treatment for pheochromocytoma. However, the perioperative period is fraught with risks due to potential catecholamine surges.

Optimizing Patient Safety Before Surgery

The guidelines underscore the importance of meticulous preoperative preparation, including:

- Alpha-adrenergic blockade to control hypertension and prevent intraoperative hypertensive crises
- Volume expansion to counteract chronic vasoconstriction and avoid postoperative hypotension
- Beta-blockade only after adequate alpha-blockade if tachyarrhythmias persist

This sequence is critical to minimizing cardiovascular complications during tumor resection.

Surgical Approaches

Minimally invasive laparoscopic adrenalectomy is the preferred approach for most localized tumors due to faster recovery and fewer complications. Open surgery is reserved for large, invasive, or malignant pheochromocytomas.

Postoperative Follow-Up and Long-Term Monitoring

The journey does not end after surgery. The Endocrine Society guidelines stress the need for lifelong follow-up because recurrences or metastases can occur, sometimes years later.

Key Aspects of Postoperative Care

- Periodic biochemical testing of plasma or urinary metanephrines to detect recurrence early
- Imaging studies if biochemical markers rise or symptoms reappear
- Monitoring for complications such as adrenal insufficiency in bilateral adrenalectomy cases

Ongoing surveillance is vital for maintaining patient health and quality of life.

Implications for Clinical Practice and Patient Outcomes

Integrating the pheochromocytoma endocrine society guidelines into clinical practice fosters a multidisciplinary approach, combining endocrinology, surgery, genetics, and radiology expertise. This coordinated care model translates into:

- Reduced diagnostic delays
- Safer surgical interventions
- Personalized treatment plans based on genetic insights
- Improved long-term prognosis and survival rates

For patients, this means clearer communication, better symptom control, and more informed decisions about their health.

Emerging Trends and Future Directions

While the current guidelines provide a robust framework, ongoing research continues to refine pheochromocytoma management. Novel biomarkers, advanced imaging techniques, and targeted therapies are being explored. Additionally, the role of telemedicine and patient education in managing rare endocrine tumors is gaining momentum.

Clinicians are encouraged to stay abreast of updates from the Endocrine Society and to contribute to registries that enhance understanding of pheochromocytoma’s diverse presentations.

Navigating the complexities of pheochromocytoma requires a blend of clinical acumen and adherence to evidence-based recommendations. The pheochromocytoma endocrine society guidelines stand as a beacon for healthcare professionals, guiding them through diagnosis, treatment, and follow-up to ensure that patients receive the best possible care for this challenging condition.

Frequently Asked Questions

What are the key recommendations of the Endocrine Society guidelines for diagnosing pheochromocytoma?

The Endocrine Society guidelines recommend initial biochemical testing with plasma free metanephrines or urinary fractionated metanephrines for diagnosing pheochromocytoma, followed by imaging studies such as CT or MRI for tumor localization.

How do the Endocrine Society guidelines suggest managing patients with confirmed pheochromocytoma?

The guidelines advise surgical resection as the primary treatment for pheochromocytoma, preceded by alpha-adrenergic blockade to control hypertension and prevent intraoperative complications.

What genetic testing recommendations are included in the Endocrine Society guidelines for pheochromocytoma?

The guidelines recommend genetic testing for all patients with pheochromocytoma, as up to 40% may have hereditary mutations, to guide management and screen at-risk family members.

According to the Endocrine Society guidelines, when should biochemical testing for pheochromocytoma be performed?

Biochemical testing is recommended for patients with symptoms suggestive of catecholamine excess, adrenal incidentalomas, or familial syndromes associated with pheochromocytoma.

What imaging modalities does the Endocrine Society recommend for localizing pheochromocytoma?

The guidelines recommend cross-sectional imaging such as CT or MRI as first-line for tumor localization, with functional imaging like PET scans reserved for metastatic or recurrent cases.

How do the Endocrine Society guidelines address perioperative management of pheochromocytoma patients?

They emphasize preoperative alpha-adrenergic blockade for 7-14 days, volume expansion, and careful intraoperative monitoring to minimize hypertensive crises during tumor resection.

What follow-up is recommended by the Endocrine Society after pheochromocytoma surgery?

Lifelong annual biochemical testing is recommended to monitor for recurrence, along with periodic imaging if indicated by clinical or biochemical findings.

Do the Endocrine Society guidelines discuss treatment options for metastatic pheochromocytoma?

Yes, the guidelines suggest options such as radionuclide therapy, chemotherapy, and targeted therapies for metastatic pheochromocytoma, emphasizing individualized treatment plans based on tumor behavior and patient condition.

Additional Resources

Pheochromocytoma Endocrine Society Guidelines: A Comprehensive Review

pheochromocytoma endocrine society guidelines serve as a critical framework for clinicians managing this rare but potentially life-threatening neuroendocrine tumor. These guidelines synthesize current evidence and expert consensus to optimize diagnosis, treatment, and long-term management of pheochromocytomas and paragangliomas. Given the complexity of these tumors—arising from chromaffin cells and characterized by excessive catecholamine secretion—the Endocrine Society's recommendations provide a structured approach that balances precision medicine with practical clinical application.

Understanding the Scope of the Pheochromocytoma Endocrine Society Guidelines

Pheochromocytomas are catecholamine-producing tumors predominantly located in the adrenal medulla, whereas paragangliomas arise from extra-adrenal chromaffin tissue. Both entities share overlapping clinical presentations, including hypertension, headaches, palpitations, and diaphoresis, but their management nuances require careful differentiation. The Endocrine Society guidelines address these distinctions comprehensively, offering clinicians a roadmap that encompasses biochemical testing, imaging strategies, genetic screening, surgical intervention, and follow-up protocols.

The 2014 clinical practice guidelines issued by the Endocrine Society remain the most authoritative source on this topic, reflecting an extensive review of available literature and expert panel deliberations. These guidelines emphasize an evidence-based approach to improve patient outcomes while minimizing unnecessary interventions.

Diagnostic Evaluation: Biochemical and Imaging Modalities

Central to the pheochromocytoma endocrine society guidelines is the recommendation for biochemical testing as the first diagnostic step. Plasma free metanephrines or 24-hour urinary fractionated metanephrines are endorsed as the most sensitive and specific tests. These metabolites are preferred over direct catecholamine measurements due to their stability and reliability.

The guidelines caution about factors that may lead to false-positive results, such as certain medications, stress, or improper sample handling. To mitigate these, the guidelines advise standardized collection protocols, including patient preparation and posture considerations during blood draws.

Once biochemical confirmation is established, the focus shifts to localization of the tumor. The guidelines recommend cross-sectional imaging, typically with computed tomography (CT) or magnetic resonance imaging (MRI), to identify adrenal or extra-adrenal masses. MRI is favored when evaluating paragangliomas or patients with contraindications to iodinated contrast. Functional imaging modalities, such as ^123I-metaiodobenzylguanidine (MIBG) scintigraphy or positron emission tomography (PET) with specific tracers, are reserved for cases with metastatic disease or when anatomical imaging is inconclusive.

Genetic Testing and Familial Screening

One of the distinguishing features of the pheochromocytoma endocrine society guidelines is the recognition of a strong genetic component in the pathogenesis of these tumors. Approximately 30-40% of patients harbor germline mutations in susceptibility genes such as RET, VHL, NF1, SDHx, and TMEM127. This prevalence underscores the necessity for genetic counseling and testing in all patients diagnosed with pheochromocytoma or paraganglioma.

The guidelines advocate for a tiered genetic testing approach, prioritizing mutation panels based on clinical presentation, tumor location, and family history. Identifying hereditary syndromes has profound implications not only for patient management—including surveillance for associated tumors—but also for screening at-risk relatives, thereby enabling early detection and preventive care.

Preoperative Management and Surgical Considerations

Effective preoperative preparation is paramount to mitigate the risks associated with surgical resection of pheochromocytomas, primarily hypertensive crises due to catecholamine surges. The Endocrine Society guidelines strongly recommend initiating alpha-adrenergic blockade before surgery, using agents like phenoxybenzamine or selective alpha-1 antagonists, to control blood pressure and expand blood volume.

Beta-blockers may be introduced only after adequate alpha blockade to manage tachyarrhythmias, avoiding unopposed alpha stimulation that could exacerbate hypertension. Volume expansion with intravenous fluids is also encouraged to prevent postoperative hypotension.

Surgery remains the definitive treatment, with laparoscopic adrenalectomy favored for localized tumors. For large, invasive, or metastatic pheochromocytomas, open surgery or adjunctive therapies may be necessary. The guidelines emphasize a multidisciplinary approach involving endocrinologists, surgeons, anesthesiologists, and geneticists to optimize perioperative care.

Follow-Up and Long-Term Surveillance

Given the risk of recurrence and metastatic disease—even years after initial treatment—the Endocrine Society guidelines outline a structured follow-up regimen. Annual biochemical testing with plasma or urinary metanephrines is recommended indefinitely. Imaging studies are reserved for patients with genetic mutations conferring high risk, incomplete tumor resection, or biochemical evidence of recurrence.

The guidelines also highlight the importance of patient education regarding symptom recognition and the need for lifelong monitoring, particularly in hereditary cases. This vigilance allows early detection of relapse and timely intervention, which is critical for prognosis.

Comparisons with Other International Guidelines

While the Endocrine Society guidelines represent a robust and widely adopted standard, they are complemented by recommendations from other organizations such as the European Society of Endocrinology (ESE) and the National Comprehensive Cancer Network (NCCN). Notably, the ESE guidelines place greater emphasis on molecular imaging techniques and stratify genetic evaluation based on emerging genotype-phenotype correlations.

In contrast, the NCCN guidelines tend to focus more extensively on oncologic management, including systemic therapies for malignant pheochromocytomas. Nevertheless, the core principles of biochemical testing, preoperative blockade, and genetic screening align closely with the Endocrine Society's framework, underscoring a global consensus on fundamental care pathways.

Advantages and Limitations of the Endocrine Society Guidelines

The strength of the pheochromocytoma endocrine society guidelines lies in their comprehensive nature and incorporation of evolving scientific evidence. They provide clear, actionable recommendations that enhance diagnostic accuracy and patient safety. Furthermore, by integrating genetic insights, these guidelines pave the way for personalized medicine approaches.

However, some limitations exist. The rarity of pheochromocytoma means that large randomized controlled trials are scarce, leading to reliance on observational studies and expert opinion in certain areas. Additionally, rapid advances in molecular diagnostics and imaging may outpace guideline updates, potentially limiting applicability in cutting-edge cases.

Healthcare providers must therefore balance guideline adherence with individualized clinical judgment, considering the unique circumstances of each patient.

Implications for Clinical Practice and Future Directions

The pheochromocytoma endocrine society guidelines have transformed the approach to this complex endocrine disorder, fostering earlier detection and safer management. Their emphasis on multidisciplinary care and genetic evaluation aligns with contemporary trends towards holistic, patient-centered medicine.

Looking forward, integration of novel biomarkers, improved functional imaging tracers, and targeted therapies for metastatic disease are areas of active

research that may influence future iterations of these guidelines. Additionally, expanding access to genetic testing and counseling worldwide remains a critical challenge.

In summary, the Endocrine Society’s clinical practice guidelines provide an indispensable resource for endocrinologists, surgeons, and allied health professionals navigating the intricacies of pheochromocytoma diagnosis and management. Their continued refinement will be essential to meet the evolving landscape of precision endocrinology.

Pheochromocytoma Endocrine Society Guidelines

pheochromocytoma endocrine society guidelines: Pheochromocytoma (PHEO) and Paraganglioma (PGL) Karel Pacak, David Taïeb, 2019-11-20 This book outlines some new advances in genetics, clinical evaluation, localization, therapy (newly including immunotherapy) of pheochromocytoma and paraganglioma including their metastatic counterparts. Well-known and experienced clinicians and scientists contributed to this book to include some novel approaches to these tumors. This book will serve to various health care professionals from different subspecialties, but mainly oncologists, endocrinologists, endocrine surgeons, pediatricians, and radiologists. This book shows that the field of pheochromocytoma/paraganglioma is evolving and a significant progress has been made in last 5 years requiring that health care professionals and scientists will learns new information and implement it in their clinical practice or scientific work, respectively. This book should not be missed by anybody who is focusing on neuroendocrine tumors, their newest evaluation and treatment.

pheochromocytoma endocrine society guidelines: *Recent Advances in Pheochromocytoma and Paraganglioma: Molecular Pathogenesis, Clinical Impacts, and Therapeutic Perspective, volume II* Farhadul Islam, Ichiro Abe , Suja Pillai, 2025-05-15 Pheochromocytoma and paraganglioma are the primary types of neuroendocrine tumors, although they are relatively rare compared to other tumors, originating from chromaffin tissue in the adrenal medulla and/or autonomic nervous system ganglia. Because they are so rare, these tumors may go undiagnosed or undetected. Associated symptoms like hypertension are disease non-specific and may not clinically present themselves due to the fact that catecholamines can convert into their biologically inactive forms in the tumor, reducing the appearance of other symptoms as well. These tumors produce excessive catecholamines, the effects of which are manifested through various cardiac-related symptoms, such as hypertension due to increased total peripheral resistance, heart attacks despite no prior history, non-cardiogenic pulmonary shock, oedema, arrhythmias, and sudden death. In addition, these tumors have been associated with pseudo-obstruction of the bowels, diabetic ketoacidosis, and multisystem crises involving lactic acidosis. The benign pheochromocytoma and paraganglioma can progress into highly malignant phenotypes many years after the initial diagnosis, though the exact mechanisms of this are poorly understood. These tumors are considered the most familial in humans, with 25% of such tumors being hereditary, and contain mutations in twenty-nine associated genes. Thus the genetic factors causing them are highly diverse, making them extremely heterogenic. This Research Topic aims to present recent advances in Pheochromocytoma and Paraganglioma through our understanding of the underlying molecular and genetic spectrum of pheochromocytoma and paraganglioma and their clinical applications, which could provide a better understanding of the disease, improve the clinical impacts/diagnosis, and therapeutics. We welcome reviews, original research, methods, as well as perspective articles.

pheochromocytoma endocrine society guidelines: Recent Advances in

Pheochromocytoma and Paraganglioma: Molecular Pathogenesis, Clinical Impacts, and Therapeutic Perspective Farhadul Islam, Ichiro Abe, Alfred King-yin Lam, Suja Pillai, 2021-10-14

pheochromocytoma endocrine society guidelines: *The American Cancer Society's Principles of Oncology* The American Cancer Society, 2018-03-20 Developed by the American Cancer Society this new textbook designed for a wide range of learners and practitioners is a comprehensive reference covering the diagnosis of cancer, and a range of related issues that are key to a multidisciplinary approach to cancer and critical to cancer control and may be used in conjunction with the book, The American Cancer Society's Oncology in Practice: Clinical Management. Edited by leading clinicians in the field and a stellar contributor list from the US and Europe, this book is written in an easy to understand style by multidisciplinary teams of medical oncologists, radiation oncologists and other specialists, reflecting day-to-day decision-making and clinical practice. Input from pathologists, surgeons, radiologists, and other specialists is included wherever relevant and comprehensive treatment guidelines are provided by expert contributors where there is no standard recognized treatment. This book is an ideal resource for anyone seeking a deeper understanding of cancer prevention, screening, and follow-up, which are central to the ACS's worldwide mission on cancer control.

pheochromocytoma endocrine society guidelines: A Surgeon's Guide to Sarcomas and Other Soft Tissue Tumors, An Issue of Surgical Clinics, E-Book John M. Kane III, 2022-08-12 In this issue of Surgical Clinics, guest editor Dr. John M. Kane brings his considerable expertise to the topic of A Surgeon's Guide to Sarcomas and Other Soft Tissue Tumors. In 2021, more than 13,400 new soft tissue sarcomas will be diagnosed. This issue provides a timely update for management of the most common sarcomas, including discussions of pathology, imaging, chemotherapy, radiation, and reconstruction. - Contains 13 relevant, practice-oriented topics including the implications of an unplanned sarcoma excision (the Whoops operation); the importance of preoperative pathology and the optimal biopsy of soft tissue masses; gastrointestinal stromal tumors (GIST) and the general surgeon; the evolving management of desmoid/aggressive fibromatosis; plastic surgery reconstruction of sarcoma resection defects; and more. - Provides in-depth clinical reviews on sarcomas and other soft tissue tumors, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

pheochromocytoma endocrine society guidelines: Civetta, Taylor, & Kirby's Critical Care Medicine A. Joseph Layon, Andrea Gabrielli, Mihae Yu, Kenneth E. Wood, 2017-09-19 Covering every problem encountered in today’s intensive care unit, this leading critical care textbook presents the knowledge and expertise of more than 350 global experts in this fast-changing field. Beginning with the social aspects of medicine, it then discusses monitoring and organ system pathobiology followed by specific diseases states/syndromes. Each chapter begins with immediate concerns and proceeds to broader-based discussions of relevant pathophysiologic and clinical issues.

pheochromocytoma endocrine society guidelines: Manual of Clinical Oncology Bartosz Chmielowski, Mary Territo, 2017-02-23 Concise, portable, and packed with essential information, Manual of Clinical Oncology is an indispensable resource for understanding basic science, clinical findings, and available technology as they relate to the diagnosis and management patients with cancer. The practical format provides high-yield content useful for participating in rounds ad making diagnostic and therapeutic decisions at the bedside. Edited by Dr. Bartosz Chmielowski and Dr. Mary Territo, both from UCLA School of Medicine, this eighth edition carries on the tradition of excellence set forth by longtime editor Dr. Dennis Casciato. Incorporates recent major achievements in immunotherapies, biologics, and targeted therapies. Features new chapters on the biology of cancer, immunotherapy, and cancer survivorship. Contains numerous diagnostic and treatment algorithms, as well as content on complications, for assistance with clinical decision making. Includes helpful appendices such as a glossary of cytogenetic nomenclature and combination chemotherapy regimens. Your book purchase includes a complimentary download of the enhanced

eBook for iOS, Android, PC & Mac. Take advantage of these practical features that will improve your eBook experience: The ability to download the eBook on multiple devices at one time — providing a seamless reading experience online or offline Powerful search tools and smart navigation cross-links that allow you to search within this book, or across your entire library of VitalSource eBooks Multiple viewing options that enable you to scale images and text to any size without losing page clarity as well as responsive design The ability to highlight text and add notes with one click

pheochromocytoma endocrine society guidelines: Conn's Current Therapy 2024 - E-Book Rick D. Kellerman, Joel J. Heidelbaugh, 2023-11-29 **Selected for Doody's Core Titles® 2024 with Essential Purchase designation in Family Medicine**Trusted by clinicians for more than 75 years, Conn's Current Therapy presents today's evidence-based information along with the personal experience and discernment of expert physicians. The 2024 edition is a helpful resource for a wide range of healthcare providers, including primary care physicians, subspecialists, and allied health professionals, providing current treatment information in a concise yet in-depth format. Nearly 350 topics have been carefully reviewed and updated to bring you state-of-the-art content in even the most rapidly changing areas of medicine. - Offers personal approaches from recognized leaders in the field, covering common complaints, acute diseases, and chronic illnesses along with the most current evidence-based clinical management options. - Follows a consistent, easy-to-use format throughout, with diagnosis, therapy, drug protocols, and treatment pearls presented in quick-reference boxes and tables for point-of-care answers to common clinical questions. - Incorporates electronic links throughout the text that connect the reader to apps and clinical prediction tools that can easily be accessed in practice. - Features thoroughly reviewed and updated information from multiple expert authors and editors, who offer a fresh perspective and their unique personal experience and judgment. - Provides current drug information thoroughly reviewed by PharmDs. - Features nearly 300 images, including algorithms, anatomical illustrations, and photographs, that provide useful information for diagnosis.

pheochromocytoma endocrine society guidelines: Current Surgical Therapy E-Book John L. Cameron, Andrew M. Cameron, 2016-11-29 For more than 30 years, Current Surgical Therapy has been the go-to resource for both residents and practitioners for expert advice on today’s best treatment and management options for general surgery. The 12th Edition, by Drs. John L. Cameron and Andrew M. Cameron, remains the ideal reference for written, oral, and recertifying board study, as well as for everyday clinical practice. Twelve brand-new chapters and many new contributing authors keep you up to date with recent changes in this fast-moving field, helping you achieve better outcomes and ensure faster recovery times for your patients. Presents practical, hands-on advice on selecting and implementing the latest surgical approaches from today’s preeminent general surgeons. Approaches each topic using the same easy-to-follow format: disease presentation, pathophysiology, and diagnostics, followed by surgical therapy. Discusses which approach to take, how to avoid or minimize complications, and what outcomes to expect. Helps you visualize how to proceed with full color images throughout. Trusted by generations of general surgeons as the definitive source on the most current surgical approaches, providing a quick, efficient review prior to surgery and when preparing for surgical boards and ABSITEs. Consult this title on your favorite e-reader, conduct rapid searches, and adjust font sizes for optimal readability. Features nearly 300 succinct, well-illustrated chapters that summarize today’s best treatment and management advice for a wide variety of diseases and associated surgeries. Includes twelve brand-new chapters covering islet allotransplantation; lower extremity amputations; prehospital management of the trauma patient; ERAS: colon surgery; minimally invasive pancreatic surgery; five new chapters on the breast, and more.

pheochromocytoma endocrine society guidelines: Chronic Kidney Disease and Hypertension Matthew R. Weir, Edgar V. Lerma, 2014-11-17 The treatment of hypertension has become the most important intervention in the management of all forms of chronic kidney disease. Chronic Kidney Disease and Hypertension is a current, concise, and practical guide to the identification, treatment and management of hypertension in patients with chronic kidney disease.

In depth chapters discuss many relevant clinical questions and the future of treatment through medications and or novel new devices. Written by expert authors, Chronic Kidney Disease and Hypertension provides an up-to-date perspective on management and treatment and how it may re-shape practice approaches tomorrow.

pheochromocytoma endocrine society guidelines: *Critical Care Nursing - E-Book* Linda D. Urden, Kathleen M. Stacy, Mary E. Lough, 2021-02-18 Winner of the 2nd-place American Journal of Nursing Book of the Year award in emergency/critical care nursing for 2021!**Selected for Doody's Core Titles® 2024 with Essential Purchase designation in Critical Care** Prepare for success in today's high acuity, progressive, and critical care settings! Critical Care Nursing: Diagnosis and Management, 9th Edition helps you understand and apply critical care nursing principles and concepts to clinical assessment, diagnostic procedures, and therapeutic management. Known for its comprehensive coverage, this leading textbook uses a logical, body systems organization to address the care of patients with physiological alterations. New to this edition are illustrated Patient-Centered Critical Care features aimed at humanizing the ICU as well as Next Generation NCLEX® Exam–style case studies to help you further develop your clinical judgment skills and prepare for the latest nursing licensure exam. Also ideal for CCRN® and PCCN® exam preparation, this book is a one-stop resource on the concepts and skills required for critical care nursing! - Time-tested, high-quality content addresses all aspects of today's high acuity, progressive, and critical care nursing. - Consistent organization within each body-system unit provides an efficient framework for learning, for CCRN® and PCCN® certification preparation, and for reference in clinical practice. - Comprehensive, evidence-based content is highly referenced and includes internet resources for further research and study. - Enhanced Quality and Safety Education for Nurses (QSEN) integration links text content to QSEN competencies, through the addition of QSEN-related questions in case studies, QSEN-labeled features and boxes, QSEN content icons, and highlighted QSEN information.

pheochromocytoma endocrine society guidelines: Hypertension: New Frontiers HK Chopra, 2021-03-31 Hypertension is another name for high blood pressure. It can lead to severe complications and increases the risk of heart disease, stroke, and death. Blood pressure is the force exerted by the blood against the walls of the blood vessels. Comprising more than 1000 pages, this book is a complete guide to the diagnosis and management of hypertension. Divided into 19 sections, the text begins with an introduction to hypertension, its causes, risk factors, and how it presents in different sectors of the population. The next chapters discuss diagnostic methods and echocardiography. The following sections cover hypertension associated with other disorders including heart failure, stroke, renovascular diseases, metabolic syndrome, and many more. Numerous clinical management strategies are discussed in depth, as well as cardio-oncology, nutrition, and ECMO (Extracorporeal Membrane Oxygenation – a procedure that uses a machine to take over the work of the lungs and sometimes, the heart). A complete section is dedicated to paediatric cardiology and hypertension. With an internationally recognised editor and author team, the comprehensive text is highly illustrated with clinical photographs, diagrams and tables. The book also includes full online access. Key points Comprehensive guide to diagnosis and management of hypertension comprising over 1000 pages Internationally recognised editor and author team Highly illustrated with clinical photographs, diagrams and tables Includes full online access to the book

pheochromocytoma endocrine society guidelines: Clinical Anesthesia (SAE) Dr. Nishkarsh Gupta, Dr. Anju Gupta, 2021-06-01
##

pheochromocytoma endocrine society guidelines: DeVita, Hellman, and Rosenberg's Cancer Vincent T DeVita Jr, Steven A Rosenberg, Theodore S Lawrence, 2022-09-21 The standard-setting

text in oncology for 40 years, DeVita, Hellman and Rosenberg's Cancer: Principles and Practice of Oncology, 12th Edition, provides authoritative guidance and strategies for managing every type of cancer by stage and presentation. Drs. Vincent T. DeVita, Jr., Theodore S. Lawrence, and Steven A. Rosenberg oversee an outstanding team of expert contributing authors who keep you up to date and fully informed in this fast-changing field. This award-winning reference is also continually updated on Health Library and VitalSource platforms for the life of the edition.

pheochromocytoma endocrine society guidelines: National Kidney Foundation Primer on Kidney Diseases E-Book Scott F. Gilbert, Daniel E. Weiner, 2017-09-11 Ideal for residency, fellowship, clinical practice, and board review, the National Kidney Foundation's Primer on Kidney Diseases, 7th Edition, by Drs. Scott J. Gilbert and Daniel E. Weiner, offers comprehensive coverage of adult and pediatric kidney diseases in an authoritative, practical resource. Well organized and highly readable, it covers every relevant topic in the field, from anatomy, physiology, and pathophysiology, to diagnosis and management of kidney disease, to fluid and electrolyte disorders, hypertension, dialysis, and renal transplantation. Trusted by nephrologists at all levels of experience for nearly 25 years, this powerful learning tool and clinical reference is a joint publication of Elsevier and the National Kidney Foundation. Thoroughly covers hot topics in this fast-changing field, including ongoing clinical research and changing treatment protocols. A new chapter on inherited kidney diseases, with a specific focus on APOL1 and the implications of APOL1 carrier status for kidney disease in African-Americans. A new approach to membranoproliferative glomerulonephritis, focusing on the role of complement as a way to approach both the diagnosis and treatment of these diseases. Additions to the chapter on hemodialysis, specifically incorporating information on hemodiafiltration. Updates in the management of hypertension, incorporating results from SPRINT and ACCORD as well as data on treatment of renal artery sclerosis and renal denervation into the approach for blood pressure management. Expert ConsultTM eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, and references from the book on a variety of devices.

pheochromocytoma endocrine society guidelines: Endocrinology of Aging Emiliano Corpas, Marc R. Blackman, Ricardo Correa, S. Mitchell Harman, Antonio Ruiz-Torres, 2020-09-25 According to the United Nations, the number of people aged 60 years or over in the world is projected to be 1.4 billion in 2030 and 2.1 billion in 2050. Endocrinologists and other clinicians face the challenge of caring for the elderly. To do so, they need to incorporate geriatric principles into their clinical practice. Endocrinology of Aging: Clinical Aspects in Diagrams and Images presents chapters in a way that allows the reader to incorporate concepts and main facts of complex subjects in a visual way. As the global population becomes older, the need for a deeper understanding of geriatric pathology increases, and with it, the access to educational resources for the endocrinology and metabolism of aging. - Chapters divided according to specific endocrine and metabolic systems, providing evidence-based content regarding what is known about the function of endocrine and metabolic systems altered during the aging process - Addresses physiological changes that alter the pathophysiology of the clinical picture, explaining the characteristic pathological expressions of hormonal and metabolic disorders in the advanced age - Editors and authors are clinical endocrinologists, geriatricians, internists and endocrine surgeons, with extensive global experience in clinical and experimental gerontology - Considers the patient transitioning from young adult to elderly, discussing the endocrinological challenge to discern physiology from pathology - Focuses on age as an essential factor for diagnostic and endocrine management - Includes many pictures and diagrams, making it a user-friendly reference guide for practicing physicians

pheochromocytoma endocrine society guidelines: Hypertension: A Companion to Braunwald's Heart Disease E-Book George L. Bakris, Matthew Sorrentino, 2017-01-03 The third edition of Hypertension: A Companion to Braunwald's Heart Disease, by Drs. George L. Bakris and Matthew Sorrentino, focuses on every aspect of managing and treating patients who suffer from hypertensive disorders. Designed for cardiologists, endocrinologists and nephrologists alike, this expansive, in-depth review boasts expert guidance from contributors worldwide, keeping you

abreast of the latest developments from basic science to clinical trials and guidelines. - Features expert guidance from worldwide contributors in cardiology, endocrinology, neurology and nephrology. - Covers behavior management as an integral part of treatment plans for hypertensives and pre-hypertensives. - Covers new developments in epidemiology, pathophysiology, immunology, clinical findings, laboratory testing, invasive and non-invasive testing, risk stratification, clinical decision-making, prognosis, and management. - Includes chapters on hot topics such as hypertension as an immune disease; sleep disorders including sleep apnea, a major cause of hypertension; a novel chapter on environmental pollution and its contribution to endothelial dysfunction, and more! - Equips you with the most recent guidelines from the major societies. - Updates sourced from the main Braunwald's Heart Disease text. - Highlights new combination drug therapies and the management of chronic complications of hypertension.

pheochromocytoma endocrine society guidelines: Henry's Clinical Diagnosis and Management by Laboratory Methods E-Book Richard A. McPherson, Matthew R. Pincus, 2021-06-09 For more than 100 years, Henry's Clinical Diagnosis and Management by Laboratory Methods has been recognized as the premier text in clinical laboratory medicine, widely used by both clinical pathologists and laboratory technicians. Leading experts in each testing discipline clearly explain procedures and how they are used both to formulate clinical diagnoses and to plan patient medical care and long-term management. Employing a multidisciplinary approach, it provides cutting-edge coverage of automation, informatics, molecular diagnostics, proteomics, laboratory management, and quality control, emphasizing new testing methodologies throughout. - Remains the most comprehensive and authoritative text on every aspect of the clinical laboratory and the scientific foundation and clinical application of today's complete range of laboratory tests. - Updates include current hot topics and advances in clinical laboratory practices, including new and extended applications to diagnosis and management. New content covers next generation mass spectroscopy (MS), coagulation testing, next generation sequencing (NGS), transfusion medicine, genetics and cell-free DNA, therapeutic antibodies targeted to tumors, and new regulations such as ICD-10 coding for billing and reimbursement. - Emphasizes the clinical interpretation of laboratory data to assist the clinician in patient management. - Organizes chapters by organ system for quick access, and highlights information with full-color illustrations, tables, and diagrams. - Provides guidance on error detection, correction, and prevention, as well as cost-effective test selection. - Includes a chapter on Toxicology and Therapeutic Drug Monitoring that discusses the necessity of testing for therapeutic drugs that are more frequently being abused by users. - Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.

pheochromocytoma endocrine society guidelines: Miller's Anesthesia, 2-Volume Set E-Book Michael A. Gropper, Lars I. Eriksson, Lee A. Fleisher, Neal H. Cohen, Kate Leslie, Oluwaseun Johnson-Akeju, 2024-07-18 **Selected for 2025 Doody's Core Titles® with Essential Purchase designation in Anesthesiology & Pain Medicine**Offering up-to-date coverage of everything from historical and international perspectives to basic science and today's clinical practice, Miller's Anesthesia, 10th Edition, remains the #1 reference and trusted learning resource for practitioners and trainees in this complex field. Dr. Michael Gropper leads a team of expert editors and contributing authors who provide current information on the technical, scientific, and clinical issues you face each day—whether you're managing a challenging patient care situation, preparing for the boards, or studying for recertification. - Addresses timely topics alongside foundational basic science for an in-depth and comprehensive understanding of the field - Contains thoroughly up-to-date content, including two new chapters: The Immune System: Implications for Anesthetic Management and Emergency Preparedness in Healthcare - Provides new content in key areas such as sustainability, global health equity, the effect of anesthetics on immune function, anesthesia for special populations, coverage of infectious diseases including COVID-19, and occupational exposure and safety - Offers state-of-the-art coverage of anesthetic drugs, guidelines for anesthetic practice and patient safety, new techniques, step-by-step instructions for patient

management, the unique needs of pediatric patients, and much more—all highlighted by more than 1,200 full-color illustrations (300 new to this edition) for enhanced visual clarity - Includes 40+ video clips demonstrating patient positioning, ultrasound, echocardiograms, and other imaging, and anesthetic procedures in real time

pheochromocytoma endocrine society guidelines: Hypertension - E-Book George L. Bakris, Matthew Sorrentino, Luke J. Laffin, 2023-08-29 **Selected for Doody's Core Titles® 2024 in Cardiology**Part of the renowned Braunwald family of references, Hypertension: A Companion to Braunwald's Heart Disease provides today's clinicians with clear, authoritative guidance on every aspect of managing and treating patients who suffer from hypertensive disorders. An invaluable resource for cardiologists, endocrinologists, and nephrologists, this one-stop reference covers all the latest developments from basic science to clinical trials and guidelines related to the treatment of common to complex hypertension. Now fully updated from cover to cover, the 4th Edition offers unparalleled coverage of hypertension in an accessible and user-friendly manner. - Thoroughly covers new treatment guidelines related to recent research and the latest physiologic understanding for a wide range of patients with hypertension and related co-morbidities - Includes new chapters on Hypertension in Women, Mineralocorticoid Receptor Antagonists, Exercise and Hypertension, and Telemedicine/Digital Health - Contains new or expanded content on epidemiology, pathophysiology, immunology, clinical findings, laboratory testing, invasive and non-invasive testing, risk stratification, clinical decision-making, prognosis, and management - Provides new chapter summaries and a new focus on clinical and actionable content using a streamlined, narrative format - Covers behavior management and prevention as an integral part of hypertensive and pre-hypertensive treatment plans - Highlights combination drug therapies and management of chronic complications of hypertension - Offers expert guidance from worldwide experts in cardiology, endocrinology, and nephrology, and integrates the most recent guidelines from leading organizations around the world

Related to pheochromocytoma endocrine society guidelines

Pheochromocytoma - Symptoms and causes - Mayo Clinic Usually, a pheochromocytoma forms in only one adrenal gland. But tumors can grow in both adrenal glands. With a pheochromocytoma, the tumor releases hormones that

Pheochromocytoma: Causes, Symptoms & Treatment - Cleveland A pheochromocytoma is a rare tumor that forms in the middle of your adrenal gland. It's usually benign. Symptoms include high blood pressure and headaches

Pheochromocytoma - StatPearls - NCBI Bookshelf Pheochromocytoma is a neoplasm that can be either benign or malignant and is often associated with familial syndromes such as neurofibromatosis type 1 (NF1), multiple

Pheochromocytoma: An Adrenal Gland Tumor - Johns Hopkins A pheochromocytoma is a rare type of tumor in the middle of the adrenal gland. The adrenal glands make different hormones. These hormones help keep your heart rate and blood

Pheochromocytoma - Wikipedia Pheochromocytoma (British English: phaeochromocytoma) is a rare tumor of the adrenal medulla composed of chromaffin cells and is a pharmacologically volatile, potentially lethal

Pheochromocytoma Symptoms, Treatment, Diagnosis & Prognosis Pheochromocytoma is a tumor of the adrenal glands. Symptoms include headache, sweating, palpitations, elevated blood pressure, anxiety, nausea, tremors, and more. Learn more about

Pheochromocytoma > Fact Sheets > Yale Medicine A pheochromocytoma is an adrenal tumor that makes and releases excess catecholamines. These tumors can cause serious health problems including stroke, heart attack, and even

Pheochromocytoma - Hormonal and Metabolic Disorders - MSD A pheochromocytoma is a tumor that usually originates from the chromaffin cells of the adrenal glands, causing overproduction of catecholamines, powerful hormones that induce high blood

Pheochromocytoma - NCI - National Cancer Institute Pheochromocytoma is a type of neuroendocrine tumor that grows from cells called chromaffin cells. These cells produce hormones needed for the body and are found in the adrenal glands

Pheochromocytoma | Adrenal Glands | MedlinePlus Pheochromocytoma is a rare tumor that usually starts in the cells of one of your adrenal glands. Although they are usually benign, pheochromocytomas often cause the

Pheochromocytoma - Symptoms and causes - Mayo Clinic Usually, a pheochromocytoma forms in only one adrenal gland. But tumors can grow in both adrenal glands. With a pheochromocytoma, the tumor releases hormones that

Pheochromocytoma: Causes, Symptoms & Treatment - Cleveland A pheochromocytoma is a rare tumor that forms in the middle of your adrenal gland. It's usually benign. Symptoms include high blood pressure and headaches

Pheochromocytoma - StatPearls - NCBI Bookshelf Pheochromocytoma is a neoplasm that can be either benign or malignant and is often associated with familial syndromes such as neurofibromatosis type 1 (NF1), multiple

Pheochromocytoma: An Adrenal Gland Tumor - Johns Hopkins A pheochromocytoma is a rare type of tumor in the middle of the adrenal gland. The adrenal glands make different hormones. These hormones help keep your heart rate and blood

Pheochromocytoma - Wikipedia Pheochromocytoma (British English: phaeochromocytoma) is a rare tumor of the adrenal medulla composed of chromaffin cells and is a pharmacologically volatile, potentially lethal

Pheochromocytoma Symptoms, Treatment, Diagnosis & Prognosis Pheochromocytoma is a tumor of the adrenal glands. Symptoms include headache, sweating, palpitations, elevated blood pressure, anxiety, nausea, tremors, and more. Learn more about

Pheochromocytoma > Fact Sheets > Yale Medicine A pheochromocytoma is an adrenal tumor that makes and releases excess catecholamines. These tumors can cause serious health problems including stroke, heart attack, and even

Pheochromocytoma - Hormonal and Metabolic Disorders - MSD A pheochromocytoma is a tumor that usually originates from the chromaffin cells of the adrenal glands, causing overproduction of catecholamines, powerful hormones that induce high blood

Pheochromocytoma - NCI - National Cancer Institute Pheochromocytoma is a type of neuroendocrine tumor that grows from cells called chromaffin cells. These cells produce hormones needed for the body and are found in the adrenal glands

Pheochromocytoma | Adrenal Glands | MedlinePlus Pheochromocytoma is a rare tumor that usually starts in the cells of one of your adrenal glands. Although they are usually benign, pheochromocytomas often cause the

Pheochromocytoma - Symptoms and causes - Mayo Clinic Usually, a pheochromocytoma forms in only one adrenal gland. But tumors can grow in both adrenal glands. With a pheochromocytoma, the tumor releases hormones that

Pheochromocytoma: Causes, Symptoms & Treatment - Cleveland A pheochromocytoma is a rare tumor that forms in the middle of your adrenal gland. It's usually benign. Symptoms include high blood pressure and headaches

Pheochromocytoma - StatPearls - NCBI Bookshelf Pheochromocytoma is a neoplasm that can be either benign or malignant and is often associated with familial syndromes such as neurofibromatosis type 1 (NF1), multiple

Pheochromocytoma: An Adrenal Gland Tumor - Johns Hopkins A pheochromocytoma is a rare type of tumor in the middle of the adrenal gland. The adrenal glands make different hormones. These hormones help keep your heart rate and blood

Pheochromocytoma - Wikipedia Pheochromocytoma (British English: phaeochromocytoma) is a rare tumor of the adrenal medulla composed of chromaffin cells and is a pharmacologically volatile, potentially lethal

Pheochromocytoma Symptoms, Treatment, Diagnosis & Prognosis Pheochromocytoma is a tumor of the adrenal glands. Symptoms include headache, sweating, palpitations, elevated blood pressure, anxiety, nausea, tremors, and more. Learn more about

Pheochromocytoma > Fact Sheets > Yale Medicine A pheochromocytoma is an adrenal tumor that makes and releases excess catecholamines. These tumors can cause serious health problems including stroke, heart attack, and even

Pheochromocytoma - Hormonal and Metabolic Disorders - MSD A pheochromocytoma is a tumor that usually originates from the chromaffin cells of the adrenal glands, causing overproduction of catecholamines, powerful hormones that induce high blood

Pheochromocytoma - NCI - National Cancer Institute Pheochromocytoma is a type of neuroendocrine tumor that grows from cells called chromaffin cells. These cells produce hormones needed for the body and are found in the adrenal glands

Pheochromocytoma | Adrenal Glands | MedlinePlus Pheochromocytoma is a rare tumor that usually starts in the cells of one of your adrenal glands. Although they are usually benign, pheochromocytomas often cause the

Pheochromocytoma - Symptoms and causes - Mayo Clinic Usually, a pheochromocytoma forms in only one adrenal gland. But tumors can grow in both adrenal glands. With a pheochromocytoma, the tumor releases hormones that

Pheochromocytoma: Causes, Symptoms & Treatment - Cleveland A pheochromocytoma is a rare tumor that forms in the middle of your adrenal gland. It's usually benign. Symptoms include high blood pressure and headaches

Pheochromocytoma - StatPearls - NCBI Bookshelf Pheochromocytoma is a neoplasm that can be either benign or malignant and is often associated with familial syndromes such as neurofibromatosis type 1 (NF1), multiple

Pheochromocytoma: An Adrenal Gland Tumor - Johns Hopkins A pheochromocytoma is a rare type of tumor in the middle of the adrenal gland. The adrenal glands make different hormones. These hormones help keep your heart rate and blood

Pheochromocytoma - Wikipedia Pheochromocytoma (British English: phaeochromocytoma) is a rare tumor of the adrenal medulla composed of chromaffin cells and is a pharmacologically volatile, potentially lethal

Pheochromocytoma Symptoms, Treatment, Diagnosis & Prognosis Pheochromocytoma is a tumor of the adrenal glands. Symptoms include headache, sweating, palpitations, elevated blood pressure, anxiety, nausea, tremors, and more. Learn more about

Pheochromocytoma > Fact Sheets > Yale Medicine A pheochromocytoma is an adrenal tumor that makes and releases excess catecholamines. These tumors can cause serious health problems including stroke, heart attack, and even

Pheochromocytoma - Hormonal and Metabolic Disorders - MSD A pheochromocytoma is a tumor that usually originates from the chromaffin cells of the adrenal glands, causing overproduction of catecholamines, powerful hormones that induce high blood

Pheochromocytoma - NCI - National Cancer Institute Pheochromocytoma is a type of neuroendocrine tumor that grows from cells called chromaffin cells. These cells produce hormones needed for the body and are found in the adrenal glands

Pheochromocytoma | Adrenal Glands | MedlinePlus Pheochromocytoma is a rare tumor that usually starts in the cells of one of your adrenal glands. Although they are usually benign, pheochromocytomas often cause the

Related Articles

- kanban for inventory management

- coles 7 steps occupational therapy
- the power of positive thinking author

Back to Home